Abstract:One of the most desirable targets for HBV medications is the sodium taurocholate cotransporting polypeptide (NTCP), an entry receptor for the hepatitis B virus (HBV). N-myristoylated preS1 2–48 (Myrcludex B or Hepcludex), an NTCP-binding peptide from the large surface protein of HBV, has been developed as the first-in-class entry inhibitor. However, its relatively large molecular weight contributes to increased immunogenicity and antibody production. As a result, it is preferable to look for an NTCP-binding peptide with a smaller size. To do this, we developed a human cell surface display strategy and screened peptides based on preS1-21. PreS1-21 (genotype D) was extended by 7 random amino acids and fused with mCherry and FasL transmembrane domain. The pooled constructs were transfected into HEK293 cells by using the transposon/transposase system to create a library displaying various peptides on the cell surface with red fluorescence. On the other hand, we expressed NTCP protein fused with EGFP on HEK293 and used the membrane lysate containing NTCP-GFP as the bait protein to select peptides with increased NTCP affinity. After 7 cycles of selection, the deep sequencing results revealed that some polypeptides were more than 1,000 times enriched. Further screening of the mostly enriched 10 peptides yields the peptide preS1-21-pep3. Replacing the preS1-21 sequence of preS1-21-pep3 with those from different genotypes demonstrated that the consensus sequence of genotype A–F had the best performance. The peptide (Myr-preS1-21-pep3) was synthesized and tested on the HepG2-NTCP cell model. The results showed that Myr-preS1-21-pep3 is approximately 10 times more potent than the initial peptide Myr-preS1-21 in preventing HBV infection. In conclusion, we developed a new strategy for screening peptides binding to membrane proteins and identified a new NTCP-binding peptide with a much smaller size than Hepcludex.

Screening and characterization of hepatic B virus Pre-S2 binding proteins by phage display system

Screening for PreS Specific Binding Ligands with a Phage Displayed Peptides Library

Screening, Expression and Characterization of a Novel Protein Binding to Hepatitis B Surface Antigen

Selection of HBV preS1 binding penta peptides by phage display

Screening and Identification of Interacting Proteins with Hepatitis B Virus Core Protein in Leukocytes and Cloning of New Gene C1

Identification and Characterization of Peptides That Interact with Hepatitis B Virus Via the Putative Receptor Binding Site.

Screening for serum binding proteins in subjects with primary hepatocellular carcinoma using a phage display system

Screening of lymphocyte proteins interacting with hepatitis B virus X antigen by yeast-two hybrid technique

Asialoglycoprotein Receptor Interacts with the Pres1 Domain of Hepatitis B Virus in Vivo and in Vitro

Establishment of a hepatitis B virus reporter system harboring a HiBiT-tag in the PreS2 region.

Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase

Interaction of S17 Antibody with the Functional Binding Region of the Hepatitis B Virus Pre-S2 Epitope

Screening of a new gene C-12 coding for a hepatitis B virus core antigen interacting protein in hepatocytes by yeast-two hybrid technique

Efficient Inhibition of Hepatitis B Virus Infection by a Pres1-Binding Peptide

[Expression, Purification and Characterization of HbsAg Binding Protein in Pichia Pastoris].

Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library

The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry.

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

Establishment of a human cell line with a surface display system for screening and optimizing Na+-taurocholate cotransporting polypeptide-binding peptides

A new fluorescent based screening system for high throughput screening of drugs targeting HBV-core and HBsAg interaction

Characterization and Clinical Application of a Monoclonal Antibody to Hepatitis B Virus Large Surface Proteins